36E79725R0021_1.docx
DOCX document 24 KB Posted
- Attached to
- 6505--Rituximab and Biosimilars Federal contract opportunity
- Solicitation number
- 36E79725R0021
About this file
This is a presolicitation notice for RFP 36E79725R0021 announcing the VA National Acquisition Center's intent to procure Rituximab and biosimilars through an unrestricted procurement. The contract will serve multiple agencies including the VA (including CMOPs and SVH), DoD, Bureau of Prisons, Indian Health Service, and Federal Health Care Center.
The requirement includes two items: Rituximab 10MG/ML and biosimilars in 10ML vials (17,858 vials estimated annual usage) and 50ML vials (25,111 vials estimated annual usage). The contract will be for one base year plus four one-year options, with distribution through the VA's Pharmaceutical Prime Vendor Program. Biosimilar products must be FDA-licensed under 42 U.S.C 262 and listed in the FDA Purple Book. The solicitation will be issued around February 17, 2025, with responses due February 14, 2025, at 2:30 PM Central Time. One contract will be awarded to an offeror who can provide uninterrupted supply. The NAICS code is 325412, and the point of contact is Deb Fassl.
View the file
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Presolicitation Notice Presolicitation Notice
| SUBJECT* |
| Rituximab and Biosimilars |
GENERAL INFORMATION
| CONTRACTING OFFICE’S ZIP CODE* |
| 60141 |
| SOLICITATION NUMBER* |
| 36E79725R0021 |
| RESPONSE DATE/TIME/ZONE |
| 02-14-2025 2:30 pm CENTRAL TIME, CHICAGO, USA |
| ARCHIVE |
| 99 DAYS AFTER THE RESPONSE DATE |
SET-ASIDE
| PRODUCT SERVICE CODE* |
| 6505 |
| NAICS CODE* |
| 325412 |
PLACE OF PERFORMANCE
POSTAL CODE
COUNTRY
CONTACT INFORMATION
| CONTRACTING OFFICE ADDRESS |
| Department of Veterans Affairs |
OPAL / National Acquisition Center Building 37 1st Avenue, One Block North of Cermak Hines, IL 60141
POINT OF CONTACT*
Contract Specialist Deb Fassl Deborah.Fassl@va.gov 708-786-5894
ADDITIONAL INFORMATION
AGENCY’S URL
URL DESCRIPTION
| AGENCY CONTACT’S EMAIL ADDRESS |
| Deborah.Fassl@va.gov |
| EMAIL DESCRIPTION |
| Agency POC email |
DESCRIPTION
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0021 for an unrestrictive procurement for Rituximab for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract item(s) will be distributed through the VA’s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation 36E79725R0021 will be electronically issued in commercial product format in accordance with FAR Part 12 on or about February 17, 2025, with a tentative closing date of March 4, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: www.sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Deb Fassl. Questions can be e-mailed to: Deborah.Fassl@va.gov.
The estimated annual requirement is as follows:
| ITEM |
| DESCRIPTION |
| PKG SIZE |
(ML per Vials)
TOTAL ESTIMATED ANNUAL USAGE
(Vials)
| 1 |
| RITUXIMAB 10MG/ML AND BIOSIMILARS* |
| 10 |
| 17,858 |
| 2 |
| RITUXIMAB 10MG/ML AND BIOSIMILARS* |
| 50 |
| 25,111 |
*Proposed biosimilar products must be biological products licensed by the FDA under 42 U.S.C § 262 and must meet all biosimilar criteria described in 42 U.S.C. § 262. Additionally, Biosimilars Products must be FDA approved as a biologic medication that is compared to the innovator (the original biologic) and listed as a biosimilar to the innovator in the FDA Purple Book (https://purplebooksearch.fda.gov/).
| *=Required Field |
| Presolicitation Notice |
Presolicitation Notice
File details come from the government source that posted it. Updated .